Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial

Background and study aims: Pancreatitis is the most common complication of therapeutic endoscopic retrograde cholangiopancreatography (ERCP), and many pharmacoprophylactic approaches have been suggested, though not without controversy. The aim was to investigate the impact of combined therapy with diclofenac plus somatostatin on reducing the frequency and severity of post-ERCP pancreatitis (PEP).

Patients and methods: A prospective, double-blind, placebo-controlled trial was conducted in two tertiary referral centers, with 540 eligible patients randomized to receive either combined therapy with diclofenac 100 mg rectally 30 to 60 minutes before ERCP plus somatostatin 0.25 mg/h for 6 hours (group A), or a placebo suppository identical in appearance to the diclofenac along with saline solution (group B). Patients were clinically evaluated and serum amylase levels were determined before ERCP and at 6 and 24 hours post-procedure. Standardized criteria were used to diagnose and grade the severity of PEP. Adverse events were recorded prospectively.

Results: There were no statistical differences between the groups regarding demographic data, ERCP findings, and procedure risk factors for PEP. The overall incidence of acute pancreatitis was 7.2 %. The PEP rate was significantly lower in the patients who received the combination therapy than in controls (4.7 % vs. 10.4 %, P = 0.015). Previous history of acute pancreatitis (P = 0.001), pancreatic opacification of first-class branches and beyond (P = 0.008), and absence of pharmacoprophylaxis (P = 0.023) were identified as independent risk factors for PEP in multivariate analysis.

Conclusion: Although combined prophylactic therapy with diclofenac plus somatostatin was promising in reducing frequency of PEP, further comparative large-scale studies are needed to confirm our findings before definitive conclusions can be drawn.

• References

• 1 Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59: 845-864
• 2 Cotton PB, Garrow DA, Gallagher J et al. Risk factors for complication after ERCP: a multivariate analysis of 11497 procedures over 12 years. Gastrontest Endosc 2009; 70: 80-88
• 3 Bai Y, Gao J, Zhang W et al. Meta-analysis: allopurinol in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28: 557-564
• 4 Zheng M, Bai J, Yuan B et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol 2008; 8: 6 Available from: http://www.biomedcentral.com/1471-230X/8/6
• 5 Andriulli A, Leandro G, Federici T et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632
• 6 Shao LM, Chen QY, Chen MY et al. Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2010; 55: 1-7
• 7 Hogan WJ, Sherman S, Pasricha P et al. Sphincter of Oddi manometry. Gastrointest Endosc 1997; 45: 342-348
• 8 Schutz SM, Abbot RM. Grading ERCPs by degree of difficulty: a new concept to produce more meaningful outcome data. Gastrointest Endosc 2000; 51: 535-539
• 9 Cotton PB, Lehman G, Vennes J et al. Endoscopic sphincterotomy complication and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393
• 10 Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918
• 11 Williams EJ, Taylor S, Fairclough P et al. Risk factors for complication following ERCP: results of a large-scale prospective multicenter study. Endoscopy 2007; 39: 793-801
• 12 Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Gastrointest Endosc 2001; 54: 425-434
• 13 Cheng CL, Sherman S, Watkins JL et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101: 139-147
• 14 Gross V, Leser HG, Heinisch A et al. Inflammatory mediators and cytokines – new aspects of the pathophysiology and assessment of severity of acute pancreatitis?. Hepatogastroenterology 1993; 40: 522-530
• 15 Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase A2 in acute pancreatitis by pharmacologic agents in vitro. Scand J Clin Lab Invest 1997; 57: 401-408
• 16 Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. . Clin Pharmacokinet 1997; 33: 184-213
• 17 Cosen-Binker LI, Binker MG, Cosen R et al. Influence of nitric oxide-donating nonsteroidal anti-inflammatory drugs on the evolution of acute pancreatitis. Shock 2006; 25: 190-203
• 18 Ayoub SS, Botting RM, Joshi AN et al. Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines. Mol Cell Biochem 2009; 327: 101-110
• 19 Devière J, Le Moine O, Van Laethem JL et al. Interleukin-10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498-505
• 20 Kylänpää ML, Repo H, Puolakkainen PA. Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol 2010; 16: 2867-2872
• 21 Dumonceau JM, Andriulli A, Deviere J et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: Prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42: 503-515
• 22 Karalis K, Mastorakos G, Chrousos GP et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93: 2000-2006
• 23 Yuan Y, Gong Z, Lou K et al. Effects and mechanisms of somatostatin analogs on apoptosis of pancreatic acinar cells in acute pancreatitis in mice. J Gastroenterol Hepatol 2001; 16: 683-688
• 24 Tang WF, Wang YG, Zhu L et al. Effect of somatostatin on immune inflammatory response in patients with severe acute pancreatitis. Dig Dis 2007; 8: 96-102
• 25 Andoh A, Hata K, Shimada M et al. Inhibitory effects of somatostatin on tumor necrosis factor-alpha-induced interleukin-6 secretion in human pancreatic periacinar myofibroblasts. Int J Mol Med 2002; 10: 89-93
• 26 Murray B, Carter R, Imrie C et al. Diclofenac reduces the incidence of acute pancreatitis after ERCP. Gastroenterology 2003; 124: 1786-1791
• 27 Khoshbaten M, Khorram H, Madad L et al. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol 2008; 23: 11-16
• 28 Cheon YK, Cho YK, Watkins JL et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007; 66: 1126-1132
• 29 Elmunzer BJ, Waljee AK, Elta GH et al. A meta analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267
• 30 Nelson DB, Freeman ML. Major hemorrhage from endoscopic sphincterotomy: risk factor analysis. J Clin Gastroenterol 1994; 19: 283-287
• 31 Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy 2010; 42: 842-853
• 32 Freeman ML, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 2004; 59: 8-14
• 33 Andriulli A, Forlano R, Napolitano G et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75: 156-163
• 34 Lawrence C, Cotton PB, Romagnuolo J et al. Small prophylactic pancreatic duct stents: an assessment of spontaneous passage and stent-induced ductal abnormalities. Endoscopy 2007; 39: 1082-1085
• 35 Bakman YG, Safdar K, Freeman ML. Significant clinical implications or prophylactic pancreatic stent placement in previously normal pancreatic ducts. Endoscopy 2009; 41: 1095-1098
• 36 Dumonceau JM, Rigaux J, Kahaleh M et al. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc 2010; 71: 934-939
• 37 Cennamo V, Fuccio L, Zagari RM et al. Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials. . Endoscopy 2010; 42: 381-388
• 38 Gong B, Cennamo V, Hao L et al. Does precut technique improve selective bile duct cannulation or increase post-ERCP pancreatitis rate? A meta-analysis of randomized controlled trials.. Surg Endosc 2010; 24: 2670-2680